1).
US FDA approves Progenics' NDA for Azedra to treat unresectable, locally
advanced/metastatic pheochromocytoma/paraganglioma
|
2).
Zydus Cadila gets USFDA nod for anti-bacterial drug
3).
Krintafel (tafenoquine) is a single-dose medication for radical cure
(prevention of relapse) of P. vivax malaria. The drug is the result
of a partnership of Glaxo Smith-Kline (GSK) and Medicines
for Malaria Venture, a public-private company whose stated mission
is to reduce the burden of malaria by developing and delivering new, effective
and affordable antimalarial drugs.
Source: https://www.everydayhealth.com/malaria/treatment/fda-approves-new-drug-treat-recurrent-malaria/
4).
Aurobindo Pharma gets USFDA nod for anticoagulant
5).
The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's
treatment for low blood-platelet count or thrombocytopenia in patients with
chronic liver disease. The treatment belongs to a new class of drugs called
thrombopoietin receptor agonists TPO RA, which stimulate platelet production
